US 12,472,272 B2
Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
Kuo-Shyan Lin, Richmond (CA); François Bénard, Vancouver (CA); Hsiou-Ting Kuo, Sherbrooke (CA); Helen Merkens, Burnaby (CA); and Zhengxing Zhang, Vancouver (CA)
Assigned to PROVINCIAL HEALTH SERVICES AUTHORITY, Vancouver (CA); and THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver (CA)
Appl. No. 17/604,703
Filed by PROVINCIAL HEALTH SERVICES AUTHORITY, Vancouver (CA); and THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver (CA)
PCT Filed Apr. 16, 2020, PCT No. PCT/CA2020/050509
§ 371(c)(1), (2) Date Oct. 18, 2021,
PCT Pub. No. WO2020/210909, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/835,183, filed on Apr. 17, 2019.
Prior Publication US 2022/0233726 A1, Jul. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/04 (2006.01); A61P 35/00 (2006.01)
CPC A61K 51/0497 (2013.01) [A61K 51/0478 (2013.01); A61K 51/048 (2013.01); A61K 51/0482 (2013.01); A61P 35/00 (2018.01)] 40 Claims
 
1. A compound, wherein the compound has Formula I or is a salt or a solvate of Formula I:

OG Complex Work Unit Chemistry
wherein:
each of R1a, R1b and R1c is independently —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H, or —PO4H;
R2 is a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C1-C20 alkylenyl or alkenylenyl, or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C2-C20 heteroalkylenyl or heteroalkenylenyl;
R3 is —O—, —S—, —S(O)—, —S(O)2—, —NHC(O)—, —C(O)NH—,

OG Complex Work Unit Chemistry
R4 is —(CH2)0-3CH(R7)(CH2)0-3—, wherein R7 is (CH2)5CH3,

OG Complex Work Unit Chemistry
each of R5 and R6 is independently hydrogen or methyl;
Xaa1 is an amino acid of formula —N(R8)R9C(O)—, wherein each R8 is independently hydrogen or methyl, and wherein each R9 is independently: a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C1-C20 alkylenyl, alkenylenyl, or alkynylenyl; or a linear or branched, cyclic or acyclic, and/or aromatic or non-aromatic C2-C20 heteroalkylenyl, heteroalkenylenyl, or heteroalkynylenyl; and
RX is a radiolabeling group independently selected from: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; and a prosthetic group containing a silicon-fluorine-acceptor moiety.